RetinAI Medical AG, the leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is thrilled to announce its new strategic partnership with Boehringer Ingelheim. By leveraging RetinAI’s Discovery® platform and AI tools, alongside Boehringer Ingelheim’s research in retinal diseases, the companies aim to improve patient outcomes in geographic atrophy (GA) and revolutionize the industry.
Age-related macular degeneration (AMD) is a progressive, debilitating eye disease that affects millions of people worldwide. It is estimated that approximately 5 million people suffer from the advanced form of AMD known as geographic atrophy (GA).
Unfortunately, the number of people affected by GA increases with age, and as the population ages, the prevalence of this sight-robbing disease is expected to rise. The devastating impact of GA is far-reaching and can permanently alter one’s quality of life.
RetinAI’s AI tools are revolutionizing the way we identify novel biomarkers, and they are now being tested with Boehringer Ingelheim’s imaging datasets from clinical studies and real-world evidence to discover additional biomarkers and predictors of disease progression.
By integrating advanced digital technologies and AI, RetinAI is helping to accelerate the development of much needed treatments and providing earlier and more precise diagnoses, potentially preventing vision loss and blindness caused by retinal diseases. This is an exciting collaboration that is sure to benefit patients and healthcare providers alike.
RetinAI is thrilled to join forces with Boehringer Ingelheim, a pioneering company dedicated to developing precise treatments and leveraging digital technologies for retinal diseases. We believe this collaboration is a major step towards advancing healthcare and improving patient outcomes.
Through our innovative Discovery platform and AI tools in GA, we are proud to collaborate with Boehringer Ingelheim and strive to develop novel treatments that are specifically tailored to a patient’s retinal disease. Our goal is to revolutionize the lives of people living with retinal diseases and create a brighter future.
RetinAI Medical AG is at the cutting-edge of medical technology, developing software solutions that leverage advanced machine learning and computer vision to revolutionize clinical, research, and pharmaceutical workflows around the world.
Founded in 2017, RetinAI is committed to transforming healthcare by enabling healthcare professionals to make better, more informed decisions sooner. By collecting and analyzing health data from the eyes, RetinAI’s international team of experts is pioneering the shift from reactive to preventive medicine, to help people fight severe eye diseases.
RetinAI is revolutionizing the world of ophthalmology by partnering with experts to accelerate data analysis and achieve more targeted research. With their data management platform and AI models for Geographic Atrophy progression prediction, RetinAI can analyze datasets at-scale and uncover valuable insights into biomarker profiles and patient subgroups or outcomes. This powerful combination of technology and expertise will allow for improved study design, clinical studies and research.